News for Armata Pharmaceuticals Inc. (ARMP)

Armata Pharmaceuticals (ARMP), a clinical-stage biotechnology company, has witnessed an extraordinary surge in search activity, reportedly increasing by 22,850%

Biotech stocks, including ARMP, are witnessing a substantial increase in investor attention, driven by heightened search activity and potential upcoming develop

On May 19, 2025, Armata Pharmaceuticals (ARMP) saw its price target raised by HC Wainwright & Co. The new price target is now set at $9.00, up from the previous

PR NewswireLOS ANGELES, May 19, 2025 All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population metAP-SA02 arm

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 47.37% and 64.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals (ARMP) has announced a boost in funding, securing an extra $4.65 million from the Department of Defense. This funding is part of an ongoi

PR NewswireLOS ANGELES, May 1, 2025 Phase 1b/2a diSArm trial evaluated AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia To

Armata Pharmaceuticals (ARMP) secured an additional $4.65 million in non-dilutive funding from the U.S. Department of Defense. The funding bring

Revenue: $1.2 million for Q4 2024, falling short of the estimated $1.56 million.Net Income: Achieved net income of $2.6 million for Q4 2024, a significant impr

PR NewswireLOS ANGELES, March 20, 2025 LOS ANGELES, March 20, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Com

PR NewswireLOS ANGELES, March 12, 2025 Proceeds to be used to continue to advance development of Armata's phage product candidates LOS ANGELES, March 12, 2

PR NewswireLOS ANGELES, March 11, 2025 LOS ANGELES, March 11, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Com

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 46.43% and 230.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Revenue: Reported grant revenue of $1.0 million for Q1 2024, which is below the estimated revenue of $1.10 million.Net Loss: Recorded a net loss of $25.02 mill

The biotech industry is poised for robust growth due to increasing demand for personalized treatments, rising prevalence of chronic diseases, heightened investments in R&D, and advancements in technology. Therefore, investors...

Armata Pharmaceuticals Inc (ARMP) announced a Q3 2023 loss from operations of $(10.3) million, widening from $(8.6) million in Q3 2022.Grant revenue for Q3 202

Innoviva, Inc. is a biopharma company leveraging royalty revenues from GSK plc. INVA stock has had a rollercoaster ride, is it a buy now? Click here for my take.

/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics...